City, county to invest $4 million in smaller substance-abuse service providers
The city of Albuquerque and Bernalillo County plan to award $4 million in grants to build capacity in local behavioral health providers, officials said Wednesday.
The initiative marks the first time the two local governments have pooled funds accumulated from the opioid settlement to pay for a joint project.
Each chipped in $2 million to pay for the grant program for behavioral health providers.
"The purpose of this money is really to help the smaller nonprofits to be better positioned to be sustainable," said Dr. Wayne Lindstrom, Bernalillo County deputy manager for behavioral health.
New Mexico brought lawsuits against opioid manufacturers and retailers and reached settlements in 2022 and 2023 that were expected to bring up to $1 billion to the state to repair damage caused by the opioid crisis.
Albuquerque and Bernalillo County are expected to receive more than $150 million as their portions of the settlements.
The city so far has received about $30 million and county about $24 million, with incremental annual funding expected to continue through 2038, officials estimated Wednesday.
So far, the two governments have spent a portion of the funding.
In April, Albuquerque allocated $4.5 million to three Gateway Center projects — intended to alleviate drug use and homelessness. Bernalillo County has allocated about $1.2 million for a public awareness and education initiative called Keep New Mexico Alive.
The joint request for proposals marks the first substantive appropriation for the county and the first joint initiative with the city of Albuquerque.
The city and county last week issued a joint request for proposals inviting small-and mid-size nonprofits with an annual operating budgets of $2 million or less to submit proposals.
The intent of the initiative is to "grow, train and sustain services here locally to alleviate the impact of the opioid epidemic," said Ellen Braden, Albuquerque's deputy director of special projects and innovations. "The City Council and the County Commission were real clear in their legislation that this pot of money is really intended for capacity building."
Nonprofits have until Aug. 7 to submit their proposals. The process of scoring the proposals and selecting the winners could take up to 90 days, Lindstrom said.
"We would hope that, by the fourth quarter of the calendar (year), this money will be out the door," Lindstrom said. The money could be used for training staff, building capacity or other uses, he said.
For example, nonprofits that serve Medicaid patients but aren't set up to receive reimbursements could use the money to pursue the complex process of becoming Medicaid providers, Lindstrom said.
The city has spent substantially more of the settlement money than the county.
In May, Mayor Tim Keller signed legislation that allocated $4.5 million from opioid settlement money to fund three Gateway Center projects intended to alleviate drug use and homelessness in Albuquerque.
The largest allocation, $2.25 million, was designated for a Medical Sobering Center to provide detoxification services for up to 50 people. That facility is expected to open later this summer.
Another $1.4 million was allocated to the First Responder Receiving Area, a facility where police and other first responders can transport individuals in need of drug and mental health services outside regular hours.
Another $950,000 was allocated to Gateway Recovery, a city-owned community of 46 tiny homes where individuals recovering from addiction can reside and receive treatment for a year.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Ketamine's Antidepressant Action May Depend on Opioid System
Activation of the body's opioid system may be required for ketamine's antidepressant effects, new research hinted. In a small study of adults with major depressive disorder, taking the opioid blocker naltrexone before a low-dose ketamine infusion both blunted the surge in glutamate — a key brain chemical linked to mood — and reduced ketamine's rapid antidepressant benefit the next day. 'These results suggest that opioid receptors help mediate ketamine's effects and that blocking opioid receptors may lessen ketamine's acute mood-lifting action,' lead researcher Luke Jelen, MBBS, clinical lecturer in psychiatry, King's College London, London, England, told Medscape Medical News . 'However, this was a small, mechanistic study, not a treatment trial, so there is no immediate indication to change clinical practice or avoid naltrexone. Larger, dedicated clinical studies are required before recommending any alteration to current protocols,' Jelen cautioned. The study was published online on July 24 in Nature Medicine . New Mechanistic Insights Ketamine's rapid-acting antidepressant effects are thought to work by transiently elevating glutamate in the anterior cingulate cortex and other frontal regions, setting off a cascade of plasticity-related pathways. Prior animal and small human studies have suggested that activating mu-opioid receptors might be necessary for ketamine's mood benefits. To investigate, Jelen and colleagues enrolled 26 adults with moderate-to-severe depression in a randomized double-blind crossover trial separated by 3 weeks. Participants received either oral placebo or 50 mg naltrexone 1 hour before receiving intravenous ketamine (0.5 mg/kg). During the first 30 minutes of each infusion, they measured brain glutamatergic activity in the anterior cingulate cortex using functional magnetic resonance spectroscopy. Depressive symptoms were measured before and 24 hours after infusion, when ketamine's antidepressant effects peak, using the Montgomery-Åsberg Depression Rating Scale (MADRS). Compared with placebo, pretreatment with a single 50-mg dose of oral naltrexone reduced the brain's glutamatergic response and dampened the average improvement on MADRS measured 24 hours later, the researchers observed. Specifically, the glutamate signal climbed significantly during ketamine when participants had taken placebo, but the rise was significantly smaller when they had taken naltrexone ( P = .029; Cohen's d = 0.34). 'We also identified a sex-related effect: The attenuating effect of naltrexone on glutamate activity appeared more pronounced in males with depression than in females with depression,' Jelen said. Alongside the attenuation of ketamine-induced glutamatergic activity, naltrexone pretreatment also led to less marked reductions in clinician-rated MADRS scores 24 hours after infusion — equating to a 28% attenuation in the main effect of ketamine ( P = .023), the researchers reported. Reductions in self-reported depressive measures were numerically lower in the presence of naltrexone than in the presence of placebo, but the differences were not statistically significant. 'The possibility of an opioid mechanism underlying the antidepressant mechanisms of ketamine has been a recent subject of considerable debate. Our study provides evidence that opioid system activation may contribute to the acute antidepressant effects of ketamine,' the authors wrote. Looking ahead, Jelen told Medscape Medical News , a larger, well-powered study should include a true placebo-infusion arm to disentangle naltrexone's effects on both ketamine and placebo responses. He also noted that adding PET imaging would directly quantify opioid-receptor engagement, and prespecified analyses by sex are essential, given the stronger glutamate-dampening effect observed in men. 'Understanding more about how ketamine works can lead to treatment being personalized for different people, which is vital for creating safe and effective treatments,' Jelen said.
Associated Press
17 hours ago
- Associated Press
Ibogaine by David Dardashti Warns of Kratom's ‘Gateway' Dangers, Citing Alarming Trend in Patient Addiction Cases
WESTCHESTER, FL - August 4, 2025 - As the FDA intensifies its crackdown on the potent kratom compound 7-hydroxymitragynine (7-OH), the addiction treatment center Ibogaine by David Dardashti is issuing a critical warning based on alarming clinical trends. The clinic's founder, David Dardashti, is speaking out about the substance's deceptive role as a gateway to more dangerous opioids, based on a sharp increase in patients seeking treatment for kratom dependency at his facility. The recent FDA actions targeting concentrated 7-OH products—dubbed 'legal morphine' by some researchers—underscore a danger the clinical team at Ibogaine by David Dardashti sees daily. The clinic has witnessed a significant increase in patients arriving with a primary or secondary addiction to kratom, often after being misled by marketing that promotes it as a safe, herbal alternative to opioids. This firsthand clinical data forms the basis for their urgent public warning. 'We are seeing a disturbing pattern,' states David Dardashti. 'Patients come to us after starting with kratom, thinking it's a safe, natural remedy. They don't realize they are developing a true opioid dependency until it's too late. The initial effects fade, tolerance builds, and suddenly they are facing a full-blown addiction with severe withdrawals. The next logical step for many is to seek out something stronger and deadlier, like fentanyl. We are on the front lines of this trend, and it is alarming.' As referenced in recent reports, experts confirm that while the kratom leaf itself may be mild, concentrated extracts containing 7-OH are significantly more potent and act as pure opioids. This creates the dangerous cycle of dependency that the clinic observes. Users require ever-increasing doses, eventually finding that the legal substance no longer satisfies the addiction it created, driving them toward the illicit drug market. Despite the alarming trend, the team at Ibogaine by David Dardashti reports significant success in treating kratom addiction and offers a message of hope. Based on extensive clinical experience, the center has found a notable distinction in the recovery process for these patients. 'The good news in this growing crisis is that we've found that individuals dependent on kratom can be brought back to sobriety with less difficulty than those entrenched in long-term Suboxone or fentanyl use,' Dardashti explains. 'Ibogaine therapy works to reset the brain's neurotransmitters and interrupt addiction at the source. For our kratom patients, the process is often smoother and the path to a full recovery is remarkably clear. Our goal is to intervene effectively before the addiction escalates into a far more tragic story.' About Ibogaine by David Dardashti: Ibogaine by David Dardashti is a leading treatment center dedicated to helping individuals overcome chemical dependency through a unique combination of ibogaine therapy and holistic care. Founded by David Dardashti, the clinic leverages extensive clinical experience to provide a safe, medically supervised environment for profound psycho-spiritual healing and neurological reset, offering a definitive interruption to the cycle of addiction. Media Contact Company Name: Ibogaine By David Dardashti Contact Person: Cole Barressi Email: Send Email Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Ibogaine by David Dardashti Warns of Kratom's 'Gateway' Dangers, Citing Alarming Trend in Patient Addiction Cases
Medscape
a day ago
- Medscape
FDA Calls for Better Opioid Safety Labeling
The FDA is requiring manufacturers of opioid pain medications to update safety labels to better emphasize risks linked to their long-term use, the agency announced in a new Drug Safety Communication. The changes are based on observations from a May meeting between the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee, which met to discuss two postmarketing requirement studies that assessed risk for abuse, addiction, and overdose in long-term use of opioid analgesics. One of the observational studies showed that over 12 months of use, 1%-6% of the more than 2000 total participants met criteria for opioid addiction, 9% met criteria for prescription opioid abuse, and 22% met criteria for prescription opioid misuse. In the second study, 5-year cumulative incidence estimates for opioid overdose-related death ranged from 1.5%-4.0%. In addition, 17% of first opioid overdoses over the entire 5-11 year study period were fatal. The new safety-labeling requirements are a result of these findings, committee and public comments from the meeting, and recognition that there is currently an 'absence of adequate and well-controlled studies on long-term opioid effectiveness,' the FDA noted in a press release. 'The death of almost 1 million Americans during the opioid epidemic has been one of the cardinal failures of the public health establishment,' FDA commissioner Marty Makary, MD, said in the release. 30-Day Warning The FDA has also called for a new prospective, randomized controlled trial to be conducted that will focus primarily on assessing risks and benefits of opioids used over the long term. For now, the updated labeling should include a better explanation of risks, stronger warnings about higher doses, clarification about use limits, an emphasis that long-acting or extended-release opioids should only be used if shorter-acting opioids or other medications have proven inadequate, and a reminder about serious harm that can come if a patient who becomes physically dependent does not stop opioid use. Additionally, the revised labels should provide information on possible opioid-related problems with the esophagus; on opioid overdose reversal agents; on toxic leukoencephalopathy, which can occur after overdose; and on negative drug-drug interactions, including gabapentinoids. 'This long-overdue labeling change is only part of what needs to be done — we also need to modernize our approval processes and postmarket monitoring,' Makary said. The release noted that OxyContin's drug application was first approved without supportive long-term use data. The FDA added that manufacturers have 30 days to submit the newly required labeling updates for review.
